Technical Support

Michael Petka, Director of IT

Michael PetkaMichael joined Gynecologic Oncology Associates in June 2013 and serves as the Director of Information Technologies. Michael has more than 18 years of information technology experience in the healthcare industry. He oversees EMR services, electronic data interfaces with several laboratories to provide physicians with timely information for patient care, as well as a patient portal that allows patients to see their results and communicate with physicians.

Previously, he served as the Director of IT for various oncology laboratories such as Oncotech/Exiqon and Ovagene Oncology. He has designed and developed laboratory information management systems (LIMS) that include labs such as EDR (Extreme Drug Resistance), IHC, DNA, FISH, Flow cytometry, PCR, qPCR, and cytogenetics. Coupling the data from these labs with patient characteristics/profiles, he created a bioinformatics environment to study genomic data, enabling rapid data mining and analysis. Michael developed several scoring systems that determine potential treatment plans for patients including chemo drug selection, radiation, or a combination of therapy. Mr. Petka has been a consultant for various oncology laboratory startups as well as established laboratories. He also designed and created a database and analytical environment for the Clearity Foundation, an organization that assists indigent women with gynecologic cancers helping physicians make better-informed treatment decisions, based on molecular profiling of tumors. Finally, Michael worked at Northrop Grumman’s ATDC Advanced Technology Design Center where he was a group leader/analyst of the advanced software methods group supporting survivability and mission effectiveness analysis. Michael received his bachelor’s degree in Mathematics from the University of California at Irvine.

Michael can be reach at 949-642-1361 ext 246

 

Michael is also the Director of IT at Nancy Yeary Women’s Cancer Research Foundation

Here is an event that will be shaping the future of medicine.

ai22